Navigation Links
Infinata Implements “Clear Quality” Initiative to Optimize Reliability and Usability of Data, Reports and Analysis for Biopharma and Wealth Management Solutions

Norwood, MA (PRWEB) April 04, 2013

Infinata, part of the Financial Times Group of companies, is a leading provider of business intelligence solutions including BioPharm Insight™, BioPharm Clinical™, High Net Worth Insight™ and wealthmonitor™. Today the company announced the launch of its corporate-wide Clear Quality initiative to optimize reliability and usability of its cloud-based solutions.

With more than 250 individual quality checks and processes, Clear Quality formalizes Infinata’s commitment to ensuring every one of its hundreds of thousands of data points is as current and accurate as possible for three primary goals:

  •     Data Integrity – Underlying internal and external data sources are current and accurate, ensuring reliable reports and up-to-date analysis
  •     Consistency – Results and recommendations from diverse searches reach uniform conclusions and are presented in a familiar manner for a seamless user experience
  •     Accessibility – Our streamlined and intuitive interface is constantly refined to reduce the number of clicks from a customer’s inquiry to an actionable result

“Infinata was founded over a decade ago by data aggregation and integration experts,” said Ruth McHenry, Managing Director of Infinata. “As the big data requirements of global biopharmaceutical and financial services industries mature, simply providing data is no longer sufficient. Infinata stays ahead of this curve by innovating with services, features and analysis which provide practical answers based on trustworthy data rather than ambiguous facts and figures.”

Continued McHenry, “Clear Quality is a robust, formal and transparent commitment to customers who rely on Infinata solutions for the information edge they need to gain a competitive advantage and dominate their global markets.”

To learn more about Infinata’s solutions, visit

About Infinata, Inc.

Featuring a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of Mergermarket, part of the Financial Times Group of companies and a division of Pearson plc.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Galien Foundation Appoints Kimberly Ha of Infinata’s BioPharm Insight to US Advisory Board
2. Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
3. Infinata’s BioPharm Insight Releases Licensing League Tables Report for 4Q12 and YE12
4. Infinata's BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
5. Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
6. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
7. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
8. Northwest Bio Implements Major Balance Sheet Clean-Up
9. Clinilabs Launches Research Volunteer Authentication Initiative Choosing Verified Clinical Trials to Stop Dual Enrollment in Clinical Trials
10. Strategic Approach for R&D Is Goal at National Photonics Initiative Event Co-Sponsored by SPIE
11. lifeIMAGE Announces No-Cost Service for Hospitals to Give Patients Secure Access to Medical Imaging, Pledges Support for the Blue Button Initiative
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... 2016 Andrew D ... Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):